What it’s for
- Studied for small changes in blood pressure
- Marketed for clot-related claims that remain unproven clinically
An enzyme preparation derived from natto and marketed for fibrinolytic or cardiovascular effects.
Purpose, evidence and practical considerations.
Small trials suggest a modest blood-pressure signal, but there is no proof that nattokinase clears arteries or prevents heart attack or stroke. Potential bleeding and medicine interactions are central limitations.
Confidence: weak
Potential bleeding is the central concern. Avoid combining nattokinase with anticoagulants, antiplatelet drugs or before surgery unless a clinician specifically approves it. Soy allergy, pregnancy, bleeding disorders and prior hemorrhagic stroke require particular caution.
Nattokinase has fibrinolytic activity in laboratory systems and may influence coagulation or blood-pressure pathways. Small human trials report modest blood-pressure changes, but claims that capsules remove arterial plaque or prevent clots are not established clinical outcomes.
Regulatory status: Dietary supplement; not an approved anticoagulant, blood-pressure medicine or treatment for atherosclerosis.
How people use it, with their schedules, context and original sources.
10,000 units a day (reported by Peter Diamandis, Apr 2026) · Daily
Reviewed dose and timing context, separate from what public protocols report.
Trials commonly used product-defined fibrinolytic units such as 2,000 FU daily for about eight weeks; milligrams alone are not interchangeable between extracts.
Amount and timing patterns reported in public protocols; these are observations, not instructions. Private and hidden usage is excluded.
1 public example — useful context, not a reliable distribution.
1 public example — useful context, not a reliable distribution.
daily
These share a protocol with this intervention. This does not establish that they work together or are suitable alternatives.